Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis

Shand, James A; McEneaney, David; Menown, Ian

doi:10.1136/hrt.2011.223404

Cited by 7 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 We agree with their summary that when used in isolation, H-FABP may not offer a diagnostic advantage over the current troponin standard. However, it should be noted that in five of the included studies constituting 1573 patients (42% of the pooled cohort), no information on symptom duration was available.…”

supporting

confidence: 66%

Correction

2011

Heart

View full text Add to dashboard Cite

supporting

confidence: 66%

Correction

2011

Heart

View full text Add to dashboard Cite

“…H‐FABP is abundantly expressed in various tissues such as liver, intestine, heart, muscles, adipocytes, brain, testis, and peripheral nervous system. It is responsible for carrying fatty acids into mitochondria for the purposes of beta‐oxidation and energy supply 16 …”

Section: Introductionmentioning

confidence: 99%

“…16 Due to lower molecular mass and cytoplasmic nature, H-FABP can be released rapidly into the blood flow following the occurrence of myocardial injury. 16 The diagnostic potential of H-FABP biomarker for myocardial injuries was first discovered in 1988 by Professor Jan Glatz (Maastricht, Netherlands). 17 However, the information on the prognostic value of this biomarker in COPD is quite limited.…”

mentioning

confidence: 99%

The relationships between serum heart‐type fatty acid‐binding protein and right ventricular echocardiographic indices in chronic obstructive pulmonary disease

Avesta

Aslani

Parham

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

Background Heart‐type Fatty Acid‐Binding Protein (H‐FABP) has been used in the diagnosis of myocardial damage. In this study, we assessed the relationships between serum H‐FABP as a marker of cardiac injury and right ventricle (RV) echocardiographic indices in patients with stable COPD. Materials and methods In this case‐control study, 84 participants were investigated (50 COPD patients and 34 healthy subjects). After obtaining consent, 3 mL of fasting whole blood sample was collected from each of the participants to test their serum H‐FABP. Echocardiography was performed on all participants by cardiologists. Results Serum H‐FABP was found to be significantly correlated with smoking history (P < 0.01), Systolic Pulmonary Artery Pressure (S‐PAP), RV Wall Thickness (RV‐WT), and Tricuspid annulus posts systolic excursion (TAPSE) (P < 0.01 for all). RV Basal Diameter (RV‐BD), RV Mid Diameter (RV‐MD), and Fractional area change percentage (FAC%) were not observed to have any correlation with serum H‐FABP. Also, the comparative analysis showed statistically significant differences between mean RV‐MD (P < 0.001), RV‐BD, FAC%, S‐PAP, RV‐WT (P < 0.001), and TAPSE (P < 0.05) of patients at different GOLD stages. There was a significant correlation between the adjusted serum level of H‐FABP and the airflow limitation based on FEV1 (P < 0.001). Conclusion The correlation between serum H‐FABP and RV echocardiographic indices such as S‐PAP, RV‐WT, and TAPSE, can be related to RV function in COPD patients. Moreover, RV echocardiographic indices are significantly correlated with the severity of COPD as classified in various GOLD stages.

show abstract

“…The Authors' reply We thank Shand et al for their comments1 on our systematic review and meta-analysis 2…”

mentioning

confidence: 99%